Bain Capital Life Sciences Investors’s Solid Biosciences SLDB Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$70.6M	Buy	9,808,819 +1,897,150	+24%	+$12.2M	6.37%	6
2025 Q4	$44.6M	Hold	7,911,669	–	–	3.42%	6
2025 Q3	$48.8M	Hold	7,911,669	–	–	3.24%	8
2025 Q2	$38.5M	Hold	7,911,669	–	–	4.82%	7
2025 Q1	$29.3M	Buy	7,911,669 +3,877,087	+96%	+$16.6M	4.33%	7
2024 Q4	$16.1M	Hold	4,034,582	–	–	1.9%	11
2024 Q3	$28.1M	Hold	4,034,582	–	–	2.93%	8
2024 Q2	$22.9M	Hold	4,034,582	–	–	2.51%	10
2024 Q1	$53.7M	Buy	4,034,582 +904,160	+29%	+$8.46M	4.32%	9
2023 Q4	$19.2M	Hold	3,130,422	–	–	1.84%	14
2023 Q3	$7.89M	Hold	3,130,422	–	–	0.88%	23
2023 Q2	$16.4M	Hold	3,130,422	–	–	1.69%	19
2023 Q1	$14.8M	Hold	3,130,422	–	–	1.85%	18
2022 Q4	$16.8M	Buy	3,130,422 +2,601,761	+492%	+$17.1M	1.88%	17
2022 Q3	$3.7M	Hold	528,661	–	–	0.44%	30
2022 Q2	$4.88M	Hold	528,661	–	–	0.57%	29
2022 Q1	$9.52M	Hold	528,661	–	–	0.92%	21
2021 Q4	$13.9M	Hold	528,661	–	–	1.1%	21
2021 Q3	$19M	Hold	528,661	–	–	1.18%	19
2021 Q2	$29M	Hold	528,661	–	–	1.9%	13
2021 Q1	$43.9M	Buy	528,661 +57,971	+12%	+$6.41M	2.48%	10
2020 Q4	$53.5M	Buy	470,690 +212,612	+82%	+$13.4M	3.36%	9
2020 Q3	$7.86M	Hold	258,078	–	–	0.73%	20
2020 Q2	$11.3M	Hold	258,078	–	–	1.19%	15
2020 Q1	$9.25M	Hold	258,078	–	–	1.56%	11
2019 Q4	$17.2M	Hold	258,078	–	–	2.57%	8
2019 Q3	$40M	Buy	258,078 +125,448	+95%	+$14.2M	10.31%	3
2019 Q2	$11.4M	Hold	132,630	–	–	5.81%	4
2019 Q1	$18.3M	Hold	132,630	–	–	7.32%	5
2018 Q4	$53.3M	Hold	132,630	–	–	18.22%	3
2018 Q3	$93.9M	Hold	132,630	–	–	21.3%	2
2018 Q2	$70.9M	Hold	132,630	–	–	22.21%	2
2018 Q1	$14.9M	Buy	+132,630	New	+$44.8M	8.8%	4

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bain Capital Life Sciences Investors's SLDB Position: Q1 2026 in Review

Bain Capital Life Sciences Investors increased its Solid Biosciences (SLDB) stake by 24% in Q1 2026, buying an estimated $12.2M and bringing the position to 9,808,819 shares worth $70.6M. The position accounts for 6.37% of the portfolio, ranked #6.

Bain Capital Life Sciences Investors first reported a position in SLDB in Q1 2018 and has held it in 33 quarters since. The position peaked at $93.9M in Q3 2018. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

Bain Capital Life Sciences Investors held 9,808,819 shares of Solid Biosciences worth $70.6M as of Q1 2026.
Bain Capital Life Sciences Investors bought 1,897,150 Solid Biosciences shares in Q1 2026, an estimated $12.2M.
Solid Biosciences made up 6.37% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #6 holding.
Bain Capital Life Sciences Investors first reported a position in Solid Biosciences in Q1 2018 and has held it in 33 quarters since.
Bain Capital Life Sciences Investors's Solid Biosciences position peaked at $93.9M in Q3 2018.
150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.